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Astrocyte Elevated Gene 1 (AEG1) is an oncogene for hepatocellular carcinoma (HCC). Its role 
in HCC pathogenesis has been well studied. A pan cancer analysis of gene expression in multiple 
databases identified TATA-box binding protein associated factor 2 (TAF2) as the gene that is 
most frequently co-expressed with AEG1. TAF2 is a protein that is involved in transcription of 
genes by RNA polymerase II. It is a factor that is dispensable for basal transcription but, required 
for activated transcription. It has also been shown to be involved in regulating cyclin levels and 
hence cell cycle progression. Bioinformatic analysis on data from different cancer databases 
confirmed the positive correlation of TAF2 expression with AEG1 expression, the over expression 
 
 
 
 
of TAF2 in HCC patients and poor survival of HCC patients with increasing TAF2. We confirmed 
the over expression of TAF2 in HCC cell lines using western blotting and HCC liver using 
immunohistochemistry. We established cell lines with stable knockdown of TAF2 
expression. These clones showed significant decrease in their ability to invade and migrate but 
not their proliferation ability. This is in contrast to what has been observed in previous studies. 
We hypothesize that the knockdowns do not show any decrease in cellular proliferation since the 
remaining TAF2 in the cells is sufficient to produce cyclins and keep cell cycle undisturbed. The 
knockdown of TAF2 causes an increase in E-cadherin level and decrease in Snail protein 
expression which is a known negative regulator of E-cadherin. Knockdown of TAF2 causes cells 
to become more epithelial leading to a decrease in their ability to migrate and invade. This study 
shows that TAF2 is a potential oncogene that needs to be further studied. 
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CHAPTER 1 
INTRODUCTION 
 
THE PROCESS OF TRANSCRIPTION 
All cells in our body, except germ cells and red blood cells, have the same set of DNA 
fragments enclosed within their nucleus. But, brain cells are structurally and functionally 
different from liver cells. What makes two cells with the same genetic composition 
different from each other is the way their genes are expressed. A gene is a part of a DNA 
segment that provides instructions in the form of a linear sequence of nucleotides to code 
for an mRNA. This mRNA is then translated to produce a protein. Gene expression is 
thus a two-step process involving transcription and translation. In some cases, such as 
ribosomal RNAs, RNA is the final product of the gene. Hence, translation of the RNA to 
a polypeptide does not occur. Cells do not require all of their gene products, be it RNA or 
proteins, at all times. Only a subset of its genes is actively being expressed at any given 
point of time. This difference in gene expression differentiates one cell type from the other.  
 
Transcription is the first step in gene expression, wherein RNA is synthesized from a DNA 
template. Tight regulation of transcription is essential to controlling gene expression1. 
Transcription is carried out by the nuclear enzyme RNA polymerase (RNAP). Prokaryotes 
have a single RNAP enzyme that catalyzes the transcription of all of its genes whereas 
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eukaryotes have three RNAPs each involved in the synthesis of different types of RNA2. 
RNAPI transcribes ribosomal RNAs (rRNAs)3. RNAPII is responsible for the synthesis of 
mRNA precursors and non-coding RNAs like snRNA4 and microRNA5. RNAPIII 
transcribes small RNAs like transfer RNAs (tRNAs)6. RNAPII is the extensively studied of 
all three RNAPs since it is involved in the transcription of protein-coding genes.  
 
Transcription occurs in three stages-Initiation, elongation and termination. Initiation of 
transcription takes place when RNA polymerase binds to the promoter region of a gene 
and unwinds the double stranded DNA at the transcription start site. During elongation, 
RNA polymerase travels along the template DNA strand in the 5’ to 3’ direction, adding 
nucleotides to the 3’ end of the growing RNA strand7. The steps involved in termination 
of transcription differ for each RNA polymerase. Pre-mRNA transcripts produced by 
RNAPII have a unique polyadenylation signal (AAUAAA) at the 3’ end. As RNAPII creates 
this polyadenylation signal, it is recognized by two protein complexes CPSF (Cleavage 
and Polyadenylation Specificity Factor)8 and CSTF (Cleavage Stimulation Factor)9,10. 
These protein complexes then recruit other proteins to carry out RNA cleavage.  
 
TRANSCRIPTION FACTORS 
Transcription factors (TFs) are molecules that initiate and regulate the process of 
transcription. They are protein complexes with DNA binding domains that allow them to 
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bind to specific DNA sequences like promoters. They can also bind to enhancers or 
repressors resulting in activation or repression of gene expression11. Certain genes have 
varying levels of transcription. One is the basal transcription, which is usually a low level 
of expression. It is also called minimal or constitutive expression. General transcription 
factors are required for basal transcription and necessary for all genes. This low 
expression level can be enhanced to reach a high level of transcription, called activated 
transcription12. Activated transcription factors, unlike basal transcription factors, are gene 
specific.   
 
The initiation of transcription requires the binding of TFs to the core promoter element 
resulting in the recruitment of the appropriate RNAP. Several core promoter elements 
(CPEs) can bind these TFs to initiate transcription. The most important of these are TATA 
box, Initiator (Inr) element and downstream core promoter element (DPE). The TATA box 
was the first eukaryotic core promoter element to be identified. In metazoans, it is typically 
located about 25-30 nucleotides upstream of the transcription start site. The consensus 
sequence for the TATA box is 5’-TATAAA-3’13. The Initiator element is another core 
promoter element that is located -6 basepairs upstream of the transcription start site and 
continues to around +11 basepairs downstream. The consensus sequence for the Inr 
element is YYANWYY14.  The DPE is another core promoter element located about 28–
33 nucleotides downstream of the transcription start site. The DPE consensus sequence 
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is RGWYV(T)15. These CPEs can be present by themselves or in combination with other 
CPEs. For example, DPE and Inr elements are found in many promoters that lack TATA 
box. There are also promoters that contain these elements in addition to the TATA box. 
Approximately twenty four percent of human genes have a TATA-like element in their 
promoter. But, only ten percent of these TATA-containing promoters have the canonical 
TATA box. Forty six percent of human core promoters contain the consensus INR and 
thirty percent are INR-containing TATA-less genes. Forty six percent of human promoters 
lack both TATA-like and consensus INR elements16.                                                                                                                                                                                                          
 
The RNAP II transcription machinery is extremely complex made up of more than 70 
polypeptides. It involves, in addition to transcription factors, several cofactors and 
mediators that aid RNAPII enzyme in transcription17-19. RNA polymerase II preinitiation 
complex is a 31 protein 1.5 megadalton protein complex. The formation of this complex 
is important to initiate the process of transcription20-22. It is a sequential process involving 
the binding of several General Transcription Factors (GTFs) to the promoter sequence23. 
The first of these steps is the recognition and binding of the GTF Transcription Factor IID 
(TFIID) to the core promoter element. Once TFIID is bound, it recruits TFIIA and then 
TFIIB. Once these three GTFs are bound, RNA polymerase and TFIIF are recruited. 
Finally TFIIE and TFIIH are recruited completing the preinitiation complex formation24. 
TFIID is the largest of the GTFs involved in eukaryotic transcription. It is a complex made 
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up of TATA binding protein (TBP) and several associated factors called TBP associated 
factors (TAFs). TBP is the specific subunit that binds to the TATA box whereas TAFs are 
coactivators of transcription.  
 
TATA-BOX BINDING PROTEIN (TBP) ASSOCIATED FACTORS (TAFs) 
When GTFs were identified, TFIID was found to bind unambiguously to the TATA box. It 
was the only GTF that had sequence-specific DNA binding activity. TBP was the first 
constituent of TFIID to be cloned. Purified TBP was able to replace TFIID and assemble 
the PIC in vitro25. It was initially believed that TBP and TFIID were identical. However, it 
was soon found that TBP was sufficient for basal transcription, but unable to support 
activated transcription26,27. Biochemical fractionation of TFIID revealed that TBP had 
coactivators associated with it and formed a large, stable multi-subunit complex. When 
this whole complex was used, activated transcription was achieved. It was thus concluded 
that TFIID comprises not only TBP, but also TBP-associated factors (TAFs). TAFs are 
not a requirement for basal transcription but are necessary for activated transcription. 
They are dispensable for the activation of specific genes28. For example, eighty four 
percent of yeast genes are dependent upon one or more TAFs for their transcription 
whereas the remaining sixteen percent are TAF independent29. Till date, approximately 
13 TAFs have been identified so far that vary greatly in size from as low as 15 KDa to as 
high as 250 KDa30.  
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TAFs have been cloned and characterized in Yeast31,32, Drosophila33-35 and 
Humans27,36,37 revealing that they are evolutionary conserved35,38. All three species have 
various shared sequence motifs, such as WD40 repeats (yTAFII90/dTAFII80/hTAFII100), 
as well as limited sequence homology to histones H3 (yTAFII17/dTAFII40/hTAFII31), H4 
(yTAFII60/dTAFII60/hTAFII70), and H2B (yTAFII61/dTAFII30α/hTAFII20)39. Interestingly, 
human TAFII130 and Drosophila TAFII110 lack an obvious yeast homolog, suggesting 
that the yeast and metazoan TFIID complexes, despite their many similarities, may 
nevertheless differ in functionally important respects. 
 
 
ASSEMBLY OF TAFs 
TFIID is a twenty-subunit complex made up of 14 different polypeptides - TBP and 13 
TAFs. TAFs are present in single copies or two copies in the TFIID complex. The complex 
is composed of one copy of TBP and TAFs 1, 2, 3, 7, 8, 11 and 13 and two copies of 
TAFs 4, 5, 6, 9, 10 and 12. Five of the six TAFs that are present in two copies (TAF4, 5, 
6, 9 and 12) form a two-fold symmetric scaffold. TAF8 dimerises with TAF10 to form a 
TAF8–TAF10 complex in the cytoplasm. This is imported into the nucleus by importins. 
Binding of one copy of TAF8–TAF10 breaks the symmetry in core-TFIID, resulting in an 
asymmetric complex. It exhibits two distinct halves and new binding surfaces for further 
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subunits. Accretion of remaining TAFs and TBP in single copy, results in asymmetric 
clamp shaped holo-TFIID that nucleates the preinitiation complex (Fig. 1.1)40. A key 
feature in TAFs is the histone fold domain (HFD), which is present in nine out of 13 TAFs 
in TFIID. The HFD is a strong protein-protein interaction motif that mediates specific 
dimerization41.  
 
TATA BOX BINDING PROTEIN ASSOCIATED FACTOR 2 (TAF2) 
TAF2 is one of these several TAFs and has been shown to be homologous between 
Yeast (TAF150 or TMS1), Drosophila (dTAFII150) and Mammals (TAF2, CIF150 or 
hTAFII150)42,43. This 150 KDa protein forms a trimer with TAF1 and TBP and binds 
specifically to the Initiator (Inr) element found at the transcription start site of many 
genes42,44. An endogenous trimer made up of TAF2, TAF8 and TAF10 has been identified 
suggesting that this sub complex subsequently binds with other TAFs to form the 
complete PIC45. Tomography experiments have suggested that TFIID complex can alter 
between four different conformations and binding of TAF2 stabilizes TFIID in a particular 
conformation46. As with other TAFs, TAF2 is not universally required for transcription. 
Only 3 percentage of yeast genome is dependent on TAF2 for transcription29. Some of 
the potential TAF2 targets that have been identified include ribosomal proteins L44, S10 
and L7a, ISGF-3, metallothionein II and lipid kinase47. It is also involved in the expression 
of cyclins A and B1. Temperature sensitive TAF2 mutations in yeast and transient 
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knockout of TAF2 in mammalian cell lines both led to cell cycle arrest in the G2/M 
phase47,48.  
 
ROLE OF TRANSCRIPTION FACTORS IN CANCER 
Cells are the basic building blocks that make up every living system. For an organism to 
grow and function normally, it is important that their cells divide and duplicate in an 
organized manner. Cell division refers to the series of events that a cell goes through to 
produce two daughter cells. It is made up of the interphase and the mitotic phase. 
Interphase is the phase in which cells spend most of their life. It is made of G1, S and G2 
phases. During the G1 phase, the cells prepare to duplicate its DNA. DNA gets duplicated 
during S phase and the cells prepare for mitosis during G2 phase. Once the cells pass 
through interphase the mitotic phase begins. This is when cells share the duplicated DNA 
equally between two daughter cells. Mitosis is made up of prophase, prometaphase, 
metaphase, anaphase and telophase. After mitosis, some cells enter the G0 phase where 
they are in a quiescent state. Some cells like nerve cells and red blood cells that are 
terminally differentiated stay in this phase since there is no need for them to divide again. 
Adult mature hepatocytes are unique in that they stay in G0 phase until a regenerative 
process is initiated due to tissue loss or intoxication.  
  
The three checkpoints - G1, G2 and M make sure that the cell stalls its division if the 
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conditions are not right. Once the cells go through the G1 checkpoint, they are irreversibly 
committed to division. The G2 checkpoint makes sure that the DNA produced after 
replication is free of damage. If there is any kind of damage to the DNA, the DNA damage 
repair mechanism fixes the damage before the cell moves to mitosis. The M checkpoint 
makes sure that all sister chromatids are correctly attached to the spindle microtubules 
before they are pulled towards the pole during anaphase.  Several proteins are involved 
in keeping the cell cycle under control. An aberration in the level of these proteins can 
disrupt this control. When this process of cell cycle is perturbed, abnormal cell growth 
occurs. This is the primary difference between a normal cell and a tumor and explains the 
simplest definition of cancer, which is uncontrolled cell division. 
 
Several proteins are involved in this process of transforming a normal cell into a tumor. A 
broad way of classifying these proteins is as oncoproteins and tumor suppressor proteins. 
Oncoproteins enhance cell division and viability. In a cancer cell, these proteins are 
overexpressed causing abnormal cell division. On the other hand, tumor suppressor 
proteins, that are required to slow down cell division and promote cell death are down 
regulated in a cancerous state. Transcription factors have an important role to play in 
producing these RNAs and proteins at optimum levels. Changes in levels of these 
transcription factors can lead to abnormal cell division causing cancer. 
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HEPATOCELLULAR CARCINOMA 
The liver is made up of four different types of cells namely hepatocytes, kupffer cells, 
stellate cells and liver sinusoidal cells. Of these four cell types, hepatocytes are the major 
functional cells and make up 75 percent of the liver. A cancer caused due to malignant 
tumors originating in these cells is called hepatocellular carcinoma (HCC). HCC is the 
most common primary liver cancer. Approximately 70 to 90 percent of liver cancers are 
HCC49. According to Globocan 2012, it is the fifth most common cancer in men and the 
ninth common cancer in women worldwide. It is the second most common cause of death 
from cancer worldwide. The overall ratio of mortality to incidence is 0.95. The similarity 
between the incidence and mortality reflects the poor prognosis of this disease. 
 
HCC risk factors 
Most patients with HCC have liver cirrhosis49. It is a condition in which the hepatocytes 
slowly lose their proliferation capacity, preventing the liver from regenerating. As a result, 
scar tissue replaces the healthy liver tissue and partially blocks the flow of blood to the 
liver.  The development of cirrhosis is a slow and gradual process. In the early stages of 
cirrhosis, the liver continues to function. But with worsening cirrhosis, the liver fails. HCC 
can develop anytime during the progression of liver cirrhosis50. Telomerase dysfunction 
and alterations in the micro and macro environment that stimulate cellular proliferation 
are some of the ways in which liver cirrhosis can lead to HCC51. 
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HBV infection is responsible for more than 50 percent of HCC cases worldwide52. HBV is 
a partially double-stranded DNA-containing virus belonging to the Hepadnaviridae family. 
In most cases, HBV infection can cause cirrhosis and eventually HCC.  However, HBV 
can also cause HCC in the absence of cirrhosis. HBV can integrate its DNA into host cells 
and act as a mutagenic agent causing HCC53.  
HCV infection is another risk factor of HCC and accounts for approximately 30 percent of 
HCC cases globally52. HCV is an RNA virus and unable to integrate into the host 
genome54. Thus, HCV causes HCC exclusively through liver cirrhosis. HCV core protein 
enters the host cell, where it localizes in the outer mitochondrial membrane and 
endoplasmic reticulum and promotes oxidative stress. This results in the activation of key 
signaling pathways leading to HCC55. Chronic hepatitis C is more aggressive in HIV 
positive subjects, leading to cirrhosis and liver failure56.  
Chronic alcohol consumption is another important risk factor for HCC. It leads to liver 
damage through endotoxins, oxidative stress or inflammation causing HCC. It can also 
have genotoxic effect by enhancing the expression of certain oncogene expression or 
impairing the ability of cells to mend their DNA57. Chronic alcohol consumption can also 
act as a cofactor for HCC development synergistically with other risk factors like viral 
infections.  
Another important HCC risk factor, especially in developing countries is Nonalcoholic 
steatohepatitis (NASH). The major cause of NASH is obesity58. Obesity leads to non-
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alcoholic fatty liver disease, which in turn causes the inflammatory form non-alcoholic 
steatohepatitis and in turn promotes HCC59. Other risk factors of HCC include aflotoxin 
B1, pesticides, diabetes mellitus and diet57,60-62.  
 
Trends in HCC incidence 
There is a striking variation in HCC incidence rates between various countries. The 
incidence rate is highest in developing countries particularly Eastern Asia and South-
Eastern Asia, intermediate in Southern Europe and Northern America and lowest in 
Northern Europe and South-Central Asia63. Although at a global level, the major burden 
of HCC still falls on developing countries, HCC incidence has been decreasing in Asian 
countries64. This decrease can be attributed to programs to reduce aflatoxin B1 exposure 
and HBV transmission, declining rates of HCV infection in the population and other public 
health efforts65. In contrast, developed countries like the US have been experiencing an 
increase in HCC incidence66,67. Most of the increase in HCC cases can be attributed to 
the aging cohort with chronic hepatitis C infection. Increasing incidence of obesity and 
non-alcoholic fatty liver disease is another factor responsible for the rise in HCC 
incidences in the US68,69. 
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HCC treatment 
Liver transplantation is the best treatment option for patients with late cirrhosis70. Surgical 
resection is another treatment option available for patients with a single nodule, no 
cirrhosis and good liver function71,72. Local ablation with radiofrequency is the standard of 
care for patients with very early and early stage tumors that are unsuitable for surgery73. 
Transcatheter arterial chemoembolization is a minimally invasive procedure that involves 
administration of chemotherapy and embolization materials directly to a liver tumor via a 
catheter to restrict a tumor’s blood supply. This is recommended for patients with 
intermediate-stage HCC74.  Sorafenib is the only approved chemotherapy drug to treat 
HCC. It is an oral bi-aryl urea, which inhibits multiple cell surface and downstream kinases 
involved in tumor progression. Two phase III randomized placebo-controlled trials, the 
SHARP trial conducted mainly in America and Europe and a similar trial conducted in 
Asia reported improved overall survival with sorafenib75,76. In the SHARP trial, the median 
overall survival increased to 10.7 months with sorafenib compared to 7.9 months with 
placebo76. HCC is usually detected at late stages and treatment options for late stage 
HCC are minimum. This reveals the importance of finding new drug targets to develop 
HCC drugs. 
 
GENE AMPLIFICATION IN CANCER 
Gene amplification is the increase in copy number of a restricted region of a chromosome 
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arm. It a mechanism that cells use to overexpress certain genes for survival under stress 
such as during exposure to cytotoxic drugs. Some of the proposed mechanisms for the 
occurrence of gene amplification include extra replication and recombination, replication 
fork stalling and template switching, the breakage and fusion bridge cycle and double 
rolling circle replication77. It is frequently observed in some solid tumors and contributes 
to tumor evolution. MYC was the first oncogene that was proven to be amplified in a 
variety of tumor cells78-80. Later on, few chromosomal regions were found to be amplified 
to a great extent in many cancers. One such chromosomal segment that is frequently 
amplified in many cancers is the chromosomal region 8q47,48,81-84. This is the 
chromosomal region that houses the MYC oncogene. The MYC oncogene is present in 
the chromosomal region 8q24. Increasing evidence has shown that there are other 
neighboring regions in the long arm of chromosome 8 that are amplified85,86. 8q22 is one 
such region that was identified87. One of the many oncogenes present in this gene is the 
MTDH gene.  
 
ASTROCYTE ELEVATED GENE-1 IN HCC 
AEG-1/MTDH is an oncogene which is overexpressed in many common cancers88-92, and 
its expression level negatively correlates with poor survival and overall adverse 
prognosis93-96. AEG-1 overexpression induces an aggressive, angiogenic and metastatic 
phenotype whereas knockdown of AEG-1 inhibits these phenotypes in all cancers studied 
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so far. AEG-1 is transcriptionally regulated by c-Myc, an oncogene frequently upregulated 
in HCC97. The tumor suppressor miRNA miR-375, which is downregulated in HCC 
patients, targets AEG-198. In vitro and in vivo studies have shown that AEG-1 modulates 
expression of genes associated with proliferation, invasion, chemoresistance, 
angiogenesis and metastasis, and activates multiple pro-tumorigenic signaling 
pathways99. These studies indicate that AEG-1 is a valid target for HCC therapeutic 
development.  
 
TAF2 IN CANCER 
The gene encoding the protein TAF2 is present in the chromosomal region 8q24.12. This 
region is a mutational hotspot and is frequently amplified in a variety of cancers. The first 
association between TAF2 and cancer emerged in 2014 when cBioPortal for cancer 
genomics was used to analyse TAF alterations in cancer.  It was found that TAF2 exhibits 
copy number increases or mRNA overexpression in 73% of high grade serous ovarian 
cancer100. Other than overexpression, TAF2 is also hypomethylated in breast 
carcinoma101. Though TAF2 has been hypothesized as an oncogene solely based on 
bioinformatics data, no studies have looked at TAF2 in the context of cancer progression 
so far. Research has been going for decades now to better understand the role of TAF2 
in transcription. Though, the role of TAF2 in transcription at a molecular level has been 
better understood, its role in cancer progression, the downstream targets, pathways 
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regulated and interacting partners are yet to be unraveled. 
 
CANCER HALLMARKS 
Tumorigenesis refers to the production or formation of tumors. It is a multistep process, 
the progression of which depends on a sequential accumulation of mutations within tissue 
cells. Cancer is a manifestation of six essential alterations in cell physiology that 
collectively dictate malignant growth (Fig. 1.2)102. 
 
Self-sufficiency in growth signals 
Cells of the body require molecules that act as signals for them to grow and divide. Cancer 
cells, however, grow in the absence of growth stimulatory signals that normal cells require 
from their environment. Cancer cells can do this by autocrine signaling, cell surface 
receptor overexpression and integrin switching102. 
 
Insensitivity to anti-growth signals 
Cells have tight control over cell division. Tumor suppressor genes are important proteins 
in this process. These genes halt cell division if the cell fails any of the three checkpoints. 
In cancer, these tumour suppressor proteins are altered so that they don't effectively 
prevent cell division, even when the cell has abnormalities. Cancer cells also do not have 
contact inhibition, and will continue to grow and divide, regardless of their surroundings103. 
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Evasion of apoptosis 
Apoptosis or programmed cell death is initiated by cells when they are damaged or 
infected. This is required for organisms to grow and develop properly and for maintaining 
tissues of the body. Cancer cells, however, lose their ability to undergo apoptosis even 
though cells may be abnormal. The cancer cells may do this by altering the signals that 
detect the damage or abnormalities and activate apoptosis. They may also have defects 
in the downstream signaling itself, or the proteins involved in apoptosis104. 
 
Limitless replicative potential 
Cells of the body have a limited number of divisions before the cells stop division. This is 
due to the DNA at the end of chromosomes, known as telomeres shortening with every 
cell division. Once it reaches a particular length, it activates senescence and the cell stops 
dividing. Cancer cells manipulate telomerases and maintain telomeres at a length above 
the critical length105. Thus, they divide indefinitely, without initiating senescence. 
 
Sustained angiogenesis  
Normal tissues of the body require blood vessels running through them to deliver oxygen 
from the lungs. Cells must be close to the blood vessels to get enough oxygen for them 
to survive. An expanding tumor requires new blood vessels to deliver adequate oxygen 
to the cancer cells, and produces new vasculature by activating the angiogenic switch106. 
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In doing so, they control non-cancerous cells that are present in the tumor that can form 
blood vessels by reducing the production of factors that inhibit blood vessel production, 
and increasing the production of factors that promote blood vessel formation. 
 
Tissue invasion and metastasis 
Cancer cells have the ability to invade neighboring tissues. Tissue invasion is the reason 
for their dissemination around the body. Cancer cells have to undergo a multitude of 
changes in order to acquire the ability to metastasize. It is a multistep process that starts 
with local invasion of the cells into the surrounding tissues, invasion of blood vessels, 
enter the circulatory system and exit in a different site and start dividing107. 
 
MIGRATION AND INVASION IN CANCER 
Cancer metastasis is the cause of 90 percent of cancer related deaths108. It is the spread 
of cancer cells to tissues and organs beyond the primary site of tumor formation.   Cancer 
cells can exploit their intrinsic migratory ability to invade nearby tissues and the 
vasculature, and ultimately metastasize. Metastasis is a multi-step process that includes 
dissociation-the process of a single tumor cell detaching from the primary tumor, invasion-
the infiltration of the tumor cell to the stroma and invasion through the basement 
membrane, intravastion-the entry of the tumor cell into the vasculature and extravasation-
the exit of the tumor cell from the vasculature and entry into remote organs108. Once the 
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tumor cell enters the secondary organ, it can proliferate resulting in clinically detectable 
tumor or remain dormant for years109. The cytoskeletal properties of the disseminating 
tumor cells play an important role in its ability to metastasize successfully.  
Migration begins with polarization and extension of a leading front in the direction of the 
movement. Lamellipodia, filopodia, pseudopodia and invadopodia are different types of 
cell protrusions formed by migrating cells110. These protrusions are formed by actin 
polymerization. The leading front then binds to extracellular matrix proteins. This 
attachment occurs by means of cell adhesion molecules (CAMs) such as integrins and 
cadherins111. This binding causes the cell body to shrink which results in a traction force. 
This force allows the cell body to slide behind the migrating front resulting in cell 
movement. Actin-myosin contraction plays a major role in shrinking of the cell along the 
long axis. Organization of the actin-myosin skeleton is controlled by different enzymes. 
Myosin Light Chain kinase (MLCK) and Myosin Light Chain phosphatase (MLCP) are two 
enzymes that act on the light chains of myosin. The activity of these enzymes, in turn, is 
regulated by another set of enzymes, the Rho-GTPases. This group includes several 
members like Rho, Rac and CDC42 proteins112.  
As opposed to cell migration, invasion by tumor cells require the cells to degrade the 
extracellular matrix. Matrix Metalloproteases are proteases that play an important role in 
degrading the basement membrane and extra cellular matrix. Cytokines and growth 
factors regulate the expression of MMPs through the mitogen-activated protein kinases 
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pathway that includes proteins such as ERK 1/2 (extracellular regulated kinase 1/2), 
JNK/SAPK1/2 (c-Jun N-terminal kinase 1/2) and p38MAPK113,114.  
 
EPITHELIAL-MESENCHYMAL TRANSITION (EMT) 
Epithelial-mesenchymal transition (EMT) is a biologic process that allows a polarized 
epithelial cell, which normally interacts with basement membrane via its basal surface, to 
undergo multiple biochemical changes that enable it to assume a mesenchymal cell 
phenotype, which includes enhanced migratory capacity, invasiveness, elevated 
resistance to apoptosis, and greatly increased production of ECM components115,116. 
EMT is under tight control of multiple regulatory pathways. Transforming growth factor β 
(TGF-β) activity is usually enhanced during EMT117. Binding of TGF-β to its cell surface 
receptors activates Smad family of transcription factors. These smad proteins translocate 
to the nucleus and cooperate with transcription factors from the Snail and Twist family118. 
TFG-β can also activate Rho-like GTPases119. These effectors repress genes that are 
involved in cell polarity and cell-cell adhesion, such as RhoA and E-cadherin. At the same 
time, the expression of N-cadherin, another member of the cadherin family that allows for 
enhanced adhesion between mesenchymal cells, is upregulated. This change in cadherin 
expression is called cadherin switch and is a hallmark of EMT120.  
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CHAPTER 2 
MATERIALS AND METHODS 
 
Cells and culture conditions 
Hep3B cells were obtained from the American Type Culture Collection (Manassas, VA); 
QGY-7703 cells were obtained from Fudan University, China; HepG3 and Huh7 cells 
were kindly provided by Dr. Paul Dent. QGY-7703, HepG3 and Huh7 cells were cultured 
in Dulbecco's Modified Eagle Media (DMEM). Hep3B cells were maintained in Minimum 
Essential Media (MEM) alpha. RPMI 1640 media was used for culturing SNU-182 and 
SNU-449. SK Hep-1 and PLC/PRF/5 cells were cultured in Eagle’s Minimum Essential 
Media (EMEM). For generation of stable clones, Huh 7 and QGY-7703 cells transfected 
with luciferase gene (QGY-7703 luc cells) were used. All the above media were 
supplemented with 5% FBS and 0.5% penstrep. 
 
Generation of stable clones 
Huh7 and QGY-7703 luc cells were transfected with TAF2 shRNA (sc-77487-SH) or 
control shRNA (sc-108060). Transfection was performed using lipofectamine 2000 
(Invitrogen). 15 µl of lipofectamine reagent was diluted in 500 µl of Opti-MEM I reduced 
serum medium. 8 µg of TAF2 or control shRNA was diluted in 500 µl of OPTI-MEM I 
reduced serum medium. They were incubated for 5 minutes. Diluted DNA was added to 
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diluted lipofectamine 2000 reagent (1:1 ratio). The mixture was incubated for 20 minutes 
and added to a 6cm dish containing cells at 70 % confluency. After 48 hours, single cell 
suspension was plated. Individual colonies were selected, expanded and maintained in 
media containing 1 µg/ml puromycin.  
 
Western blotting  
Cells were washed twice with cold PBS and lysed on ice for 30 min in 250 ul of cold 1.5% 
n-dodecyl -D-maltoside (DDM). Cell debris were removed by centrifugation at 15,000 rpm 
for 15 min at 4°C. Protein concentrations were determined using the Bio-Rad protein 
assay system. Aliquots of cell extracts containing 30 µg of total protein were resolved in 
10% SDS-PAGE and transferred to nitrocellulose blotting membranes. Membranes were 
blocked for 1 h at room temperature in Blocking buffer (5% nonfat milk powder in TBST: 
10 mm TRIS-HCL (pH 8.0), 150 mm NaCl, 0.05% Tween 20), and then incubated 
overnight at 4 degree Celsius in Blocking buffer containing the respective primary 
antibody. After washing in TBST buffer thrice (10 min, RT), membranes were incubated 
for 1 h at room temperature in the respective secondary antibody diluted in suitable 
buffers. After washing in TBST, Enhanced Chemiluminescence(ECL) detection reagents 
were used to detect the protein of interest. 
 
q-RT-PCR 
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Cells were lysed with 700 µl of QIAzol lysis reagent and homogenized by vortexing. 140 
µl chloroform was added to separate RNA from DNA and proteins. Centrifugation at 
15,000 rpm for 15 minutes at 4℃ was done to separate the solution into three phases. 
The RNA in the upper aqueous phase was transferred to a new collection tube and 1.5 
volumes of 100% ethanol was added to precipitate the RNA out of the solution. The 
solution was pipetted into an RNeasy Mini column and centrifuged. The filter was then 
washed with wash buffers RWT and RPE (twice). The membrane was further dried by 
centrifuging at full speed for 1 minute. RNA was eluted using 50 µl RNase free water. 
Concentration of RNA was measured using the bio rad system. cDNA was synthesised 
from the extracted RNA by making a master mix composed of 2 µg RNA, 2 µl 10X buffer, 
2 µl random primers, 6.4 µl dNTP, 1 µl RNase out and 1 µl reverse transcriptase. The 
volume was made upto 20 µl using RNase free water. cDNA synthesis was performed 
using PCR. The cDNA was then probed with TAF2 or GAPDH probe.  
 
Colony formation assay 
500 cells were plated in a 6cm dish. After two weeks, the cells were fixed (with 3.7% 
formaldehyde) and stained (with 25% giemsa). The number of colonies (>50 cells) were 
counted. Colony forming ability was calculated as 
(Number of colonies counted/Number of cells plated) * 100 
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MTT assay 
1000 cells were plated in a each well of a 96 well plate. At the desired time point, (3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (MTT) reagent was added to the 
media. After 5 hours, equal volume of sodium dodecyl sulphate (SDS) was added. The 
plates were incubated at 37°C overnight. Absorbance was measured at 600 nm. 
Readings were obtained at 24, 48, 72 and 96 hours. 
 
Migration assay 
A wound healing/scratch assay was used to evaluate cell migration. Confluent cells were 
scratched with a 200 μl micropipette tip to create a cell-free area. The scratched 
monolayers images were captured at 0, 24 and 48 hours after wounding. A mark was 
made on the plates to make sure that the same area is being imaged everyday. The 
wound width was measured at the specific time points and compared. 
 
Invasion assay 
Invasion was measured by using 24-well BioCoat cell culture inserts with an 8-μ-porosity 
polyethyleneterepthalate membrane coated with Matrigel basement membrane matrix 
(100 μg/cm2). Briefly, the Matrigel was allowed to rehydrate for 2 h at 37 °C. The wells of 
the lower chamber were filled with medium containing 5% FBS. 25,000 cells were seeded 
in the upper compartment (6.25-mm membrane size) in serum-free medium. The invasion 
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assay was performed at 37 °C in a 5% CO2 humidified incubator for 22 hours. At the end 
of the invasion assay, the filters were removed, fixed (with methanol), and stained (with 
10% crystal violet). Cells on the upper surface of the filters were removed by wiping with 
a cotton swab, and invasion was determined by counting the number of cells that migrate 
to the lower side of the filter with a microscope at 100X magnification.  
 
IMMUNOFLUORESCENCE AND IMMUNOHISTOCHEMISTRY 
Normal human liver and human HCC liver were fixed on a slide for immunohistochemistry. 
For IF, primary hepatocytes, QGY-7703 cells and SNU-182 cells were plated on a 4-
chamber slide. The slides were blocked and incubated overnight in diluted TAF2 antibody. 
They were rinsed the following day and treated with fluorochrome conjugated secondary 
antibody. The amount of fluorescence was detected by confocal laser scanning 
microscopy (LSM700).  For IHC, secondary antibodies bound to horseradish peroxide 
was used and peroxidase was used to obtain staining. The distribution of the stain was 
observed under a microscope. 
 
BIOINFORMATICS 
Pan-cancer analysis of gene expression data in multiple databases was done to 
determine the genes in 8q that correlate with AEG-1 expression in 38 different cancer 
types.  
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Liver cancer samples (LIHC, n = 371) from TCGA database were analyzed to determine 
the genomic alterations in these patients in the TAF2 gene. The “R2: Genomics Analysis 
and Visualization Platform” was used to determine the correlation between expression 
levels of AEG-1/MTDH and TAF2 genes in two independent datasets. Oncomine was 
used to compare TAF2 copy number differences between HCC samples and normal liver. 
Two independent datasets, TCGA and Guichard, were used for this analysis. RNA 
expression levels in three independent datasets (Roessler Liver 2, Wurmbach Liver, Chen 
Liver) were also compared using Oncomine.  
To understand the relationship between TAF2 expression levels and patient survival, a 
Kaplan-Meier plot was obtained. Data from TCGA HCC database was used for this 
analysis.  
TCGA HCC (LIHC, n = 371) dataset was divided into two groups: TAF2 high (top 25%; n 
= 93) and TAF2 low (bottom 25%; n = 93). R program was used to identify differentially 
expressed genes between patients expressing high and low TAF2.  A heat map of top 50 
differentially modulated genes was also obtained. 
Canonical pathway analysis by ingenuity software was used to identify genes that are 
significantly upregulated and downregulated. These differentially changed genes were 
analysed using Ingenuity pathway analysis software to identify the upstream regulators 
that might lead to alterations in downstream genes. A z-score > 2 indicates activation and 
a z-score<-2 indicates inhibition. 
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STATISTICAL ANALYSIS 
All results were checked for statistical significance using the one-way ANOVA test. 
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CHAPTER 3 
RESULTS 
 
TAF2 overexpression positively correlates with AEG-1/MTDH over expression 
Pan-cancer analysis of gene expression data in multiple databases which identified 
TATA-box binding protein associated factor 2 (TAF2; 8q24) as the most frequently co-
expressed gene with AEG-1 in 36 out of 38 different cancer types (Pearson’s correlation 
coefficient r>0.5; p<3E-14). Analysis of liver cancer samples (LIHC, n = 371) from TCGA 
database confirmed our observations that TAF2 is co-expressed with AEG-1/MTDH (r = 
0.569, p<1E-16). Independent analysis using the “R2: Genomics Analysis and 
Visualization Platform” further confirmed strong positive correlation between expression 
levels of AEG-1/MTDH and TAF2 genes in two independent datasets (Fig. 2.1). 
 
TAF2 gene is amplified and over expressed in human HCC patients 
Analysis of TCGA database showed that TAF2 is amplified in approximately 20% of HCC 
patients (Fig. 2.2a). In Oncomine, two independent datasets (TCGA and Guichard) on 
HCC showed TAF2 copy number gain in HCC samples compared to normal liver (Fig. 
2.2b). At mRNA expression level three independent datasets in Oncomine showed highly 
significant increase in TAF2 mRNA levels in HCC samples versus normal liver (Table 1).  
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Patient survival decreases with increasing TAF2 expression 
We then used a Kaplan-Meier plot to determine the relationship between TAF2 
expression and patient survival. A significantly strong negative correlation (p = 0.0041) 
was observed between TAF2 expression levels and HCC (stages T2-T4) patient survival 
in TCGA database (Fig. 2.3).   
 
Genes involved in several oncogenic signaling pathways are upregulated in HCC 
patients with increased TAF2 
TCGA HCC dataset was divided into two groups-TAF2high and TAF2low. TAF2 showed 
log2fold change of 2.27 in TAF2high vs TAF2low (p = 4.77E-65). A total of 8166 differentially 
expressed genes were identified at false discovery rate (FDR) corrected p-value of 0.01. 
5327 genes were upregulated while 2839 were downregulated. A heat map of top 50 
differentially modulated genes shows tight clustering (Fig. 2.4a). Canonical pathway 
analysis by ingenuity software identified significant upregulation of genes of several 
oncogenic signaling pathways (such as ERK5, IGF-1 and HGF signaling) and marked 
downregulation of genes in EIF signaling pathway and oxidative phosphorylation resulting 
in mitochondrial dysfunction in TAF2 high group (Fig. 2.4b). Molecules involved in 
oncogenic signaling pathways (CD24, MAP4K4, HGF, VEGF) and several miRNAs were 
found to be possible upstream regulators of the differentially expressed genes. Activation 
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of cyclin D1 (CCND1) and inhibition of RB1 were identified to cluster with TAF2 high 
further indicating a role of TAF2 in regulating cell cycle.  
 
TAF2 is overexpressed in HCC 
Western blotting was done to detect TAF2 in primary hepatocytes and different HCC cell 
lines. It was found TAF2 present in primary hepatocytes was undetectable on a western 
blot. On the other hand, all the HCC lines that were used for analysis showed a much 
higher level of TAF2 protein expression (Fig 2.5b). Immunofluorescence assay was done 
to compare TAF2 expression levels between primary hepatocytes and HCC cell lines and 
showed similar results as western blotting (Fig 2.5a). Liver sections from normal subjects 
and HCC patients were used to compare the levels of TAF2 expression in vivo. It was 
found that normal liver section had much lesser staining of TAF2 compared to HCC liver 
(Fig 2.5c). 
 
Knockdown of TAF2 does not affect proliferation 
TAF2 was knocked down using shRNA. The knockdown was confirmed using western 
blotting and q-RT-PCR. Two positive clones from Huh 7 cells showed a knockdown of 60 
percent as compared to untreated cells (Fig 2.6a,c). The positive clone from QGY Luc 
7703 cells showed a knockdown of 40 percent (Fig 2.6b,d). The clones were named 
shTAF2-1 and shTAF2-2 and shTAF2-3 and used for further assays. The cells treated 
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with control shRNA did not show any difference in TAF2 expression compared to 
untreated cells and were named shCon-1 (Huh7 cells) and shCon-2 (QGY Luc cells).  
MTT and colony formation assays were done to determine the effect of the knockdown 
on proliferation. For MTT assay, the absorbance of the shCon and shTAF2 cells were 
measured at 24, 48, 72 and 96 hours and compared. There was no significant difference 
in proliferation between the cells (Fig 2.7 a,b).  
For colony formation assay, the number of colonies were counted after 3 weeks for Huh7 
cells and 2 weeks for QGY-7703 Luc cells. Representative plates after fixing and staining 
are shown in fig 2.8 c. The shCon and shTAF2 cells did not show any difference in their 
ability to form colonies (Fig 2.8 a,b).  
 
Knockdown of TAF2 inhibits migration 
Wound healing assay was done to determine if there was any difference in ability to 
migrate between the cells. At 24 hours, the wound distance in both shTAF2-1 and 
shTAF2-2 cells was higher compared to shCon-1 cells (p=0.0009 and p=0.0018). At 48 
hours, the wound distance remained higher in shTAF2-1 and shTAF2-2 cells compared 
to shCon cells (p=0.000385 and p=0.028501) (Fig 2.9 c). shTAF2-3 cells also showed a 
higher wound distance compared to shCon-2 cells at 24 and 48 hours (p=0.021 and 
p=0.041) (Fig 2.9 d).   
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Knockdown of TAF2 inhibits invasion 
Matrigel invasion assay was done to determine any difference between shCon and 
shTAF2 cells in their ability to invade the Matrigel. After fixing and staining, more cells per 
field were observed in the shCon cells compared to shTAF2 cells (Fig 2.10 a). Upon 
quantification, there was significant decrease in the number of shTAF2-1 (p=0.015727) 
and shTAF2-2 (p=0.002568) cells that had invaded the Matrigel compared to shCon-1 
cells. This result was also observed in shTAF2-3 cells (p=0.027155). 
 
Knockdown of TAF2 does not affect cyclin A or cyclin B1 expression 
To find out the reason for not observing a change in cellular proliferation in the TAF2 
knockdowns, the knockdowns and control were probed for cyclins A and B1. shTAF2-1 
and shTAF2-2 cells did not show any difference in cyclin levels as compared to shCon-1 
cells. 
 
Knockdown of TAF2 increases E-Cadherin and decrease Snail protein expression 
The knockdowns and control were probed for EMT markers: E-Cadherin and N-Cadherin. 
An increase in E-Cadherin was observed in the shTAF2-1 and shTAF2-2 cells compared 
to shCon-1 cells. There was no change in N-Cadherin levels. The knockdowns were 
probed for known regulators of E-Cadherin. Snail, which is a known negative regulator of 
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E-Cadherin showed decrease in shTAF2-1 and shTAF2-2 compared to shCon-1 cells.  
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CHAPTER 4 
FIGURES 
 
 
 
Figure 1.1: Model for holo-TFIID assembly 
 
 
 
Figure 1.2: Hallmarks of cancer 
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Figure 2.1: Positive correlation between TAF2 and AEG-1 expression in (a) tumor liver and (b) 
mixed liver sample 
 
 
 
Figure 2.2: TAF2 is amplified and exhibits copy number gain in HCC patients  
(a) Analysis of TCGA database shows the alteration frequency of TAF2 in liver cancer patients.  
(b) Analysis of TAF2 copy number alteration in HCC patients in TCGA and Guichard databases 
shows increased TAF2 copy number in HCC samples 
 
(b) (a) 
(b) 
(a) 
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Database Liver(n) HCC(n) Log2 fold p-value Rank 
Roessler Liver 2 220 225 1.954 3.88E-55 In top 3% 
Wurmbach Liver 10 35 1.866 3.57E-7 In top 2% 
Chen Liver 75 104 1.457 4.33E-9 In top 7% 
 
Table 1: TAF2 mRNA expression in HCC patients and normal subjects in three 
independent datasets 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: A Kaplan-Meier plot shows decreasing survival of HCC patients with 
increasing TAF2 expression 
 
 
 
 
37 
 
        
(a) 
 
Figure 2.4: (a) A heat map showing top 50 differentially expressed (DE) genes in TAF2high 
and TAF2low HCC patients. Canonical pathway analysis by ingenuity software showing 
genes that are (b) upregulated and downregulated in TAF2high group and (c) potential 
upstream regulators of the DE genes 
 
 
 
(b) 
(c) 
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Figure 2.5: TAF2 is over expressed in HCC cell lines and HCC liver (a) Representative 
fluorescent confocal micrographs showing TAF 2 protein expression in primary human 
hepatocytes and different HCC cell lines. (b) A western blot showing the levels of TAF 2 
protein expression in primary human hepatocytes and different HCC cell lines. 
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Figure 2.6: TAF2 is knocked down at mRNA and protein levels in cells treated with shRNA 
targeting TAF2 mRNA.  
(a) A q-RT-PCR showing the levels of TAF2 mRNA expression in untreated Huh7 cells, Huh7 
cells treated with control shRNA and Huh 7cells treated with TAF2 shRNA.  
(b) A western blot showing the levels of TAF2 protein expression in untreated Huh7 cells, Huh7 
cells treated with control shRNA and Huh 7 cells treated with TAF2 shRNA.  
(c) A q-RT-PCR showing the levels of TAF2 mRNA expression in untreated QGY-7703 Luc cells, 
QGY-7703 Luc cells treated with control shRNA and QGY-7703 Luc cells treated with TAF2 
shRNA.  
(d) A western blot showing the levels of TAF2 protein expression in untreated QGY-7703 cells, 
QGY-7703 cells treated with control shRNA and QGY-7703 cells treated with TAF2 shRNA. 
(a) 
(d) (c) 
(b) 
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Figure 2.7: TAF2 knockdown does not affect cellular proliferation.  
A bar graph showing absorbance at 600 nm for (a) shCon-1, shTAF2-1 and shTAF2-2 
and (b) shCon-2 and shTAF2-3 cells at four time points (24, 48, 72, 96 hours).  
(c) Representative colony formation plates (shCon-1 and shTAF2-2) after fixation and 
staining.  
A bar graph showing colony forming efficiency of (d) shCon-1, shTAF2-1 and shTAF2-2 
and (e) shCon-2 and shTAF2-3 cells. 
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Figure 2.8: Stable TAF2 knockdown results in decreased migration  
Representative wound healing in (a) shCon-1 and shTAF2-2 and (b) shCon-2 and 
shTAF2-3 cells after 24 and 48 hours 
(c) A bar graph representing wound distance of (a) shCon-1, shTAF2-1 and shTAF2-2 
and (b) shCon-2 and shTAF2-3 cells after 24 and 48 hours 
 
 
(a) 
(b) 
(c) (d) 
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Figure 2.9: Stable TAF2 knockdown results in decreased invasion.  
(a) Pictomicrograph of invaded cells in shCon-1, shTAF2-1, shTAF2-2, shCon-2 
and shTAF2-3.  
(b) A bar graph showing number of invading cells in (b) shCon-1, shTAF2-1 and 
shTAF2-2 and (c) shCon-2 and shTAF2-3 cells. 
(a) 
(b) (c) 
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Figure 2.10: A western blot showing E-Cadherin, N-Cadherin, Snail, cyclin A and cyclin 
B1 protein levels in shCon-1, shTAF2-1 and shTAF2-2 cells  
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CHAPTER 5 
DISCUSSION AND FUTURE DIRECTION 
 
AEG-1 is a well-established oncogene which is overexpressed in many common cancers. 
Its expression level negatively correlates with poor survival and overall adverse 
prognosis. A pan cancer analysis of gene expression data in multiple databases identified 
TATA-box binding protein associated factor 2 (TAF2) as the gene that is most frequently 
co-expressed with AEG1. Human AEG1 gene is present in the chromosomal location 
8q22.1 and TAF2 is present in the chromosomal location 8q24.1. The 8q22-24 is a region 
that is amplified in many cancers. The fact that these two genes are overexpressed to the 
same level in cancer and present in the chromosomal region which is a mutational hotspot 
for amplifications indicates that these two genes could possibly be co-amplified during 
cancer. 
 
Bioinformatic analyses have showed that levels of TAF2 overexpression positively 
correlates with AEG1 overexpression levels in different HCC datasets. These two genes 
could be working in cooperation with one another or have the same regulatory 
mechanism. It is known that AEG-1 is transcriptionally regulated by c-Myc, an oncogene 
frequently upregulated in HCC. It is possible that TAF2 is also a downstream target of c-
Myc. Data analysis from TCGA database shows that TAF2 is altered in 20% of liver 
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cancer patients. As expected, majority of these alterations are amplifications. Comparison 
of copy number differences of the TAF2 gene between HCC samples and normal liver 
and blood samples in two independent datasets showed a significant increase in the copy 
number of the TAF2 gene in HCC samples. To determine if this increase in copy number 
results in mRNA overexpression, mRNA expression levels were compared between 
normal and HCC livers in three independent datasets. We found a significant increase in 
TAF2 mRNA levels in HCC liver compared to normal liver. TAF2 was also ranked high 
(top 2%, 3% and 7%) among the mRNAs that were differentially expressed between these 
samples. It was also observed that TAF2 mRNA overexpression was not observed in 
other liver abnormalities like liver injury or cirrhosis. This leads us to the conclusion that 
TAF2 overexpression is HCC specific and could be a driver event in HCC. Analysis of a 
survival plot generated from HCC dataset in TCGA showed negative correlation between 
TAF2 expression and overall survival of HCC patients.  
 
The TCGA dataset was grouped into TAF2high and TAF2low and a heatmap showing the top 50 
genes that are differentially regulated between the two groups was generated. This map showed 
that most of the genes are overexpressed in the TAF2high group as compared to the TAF2low group. 
Canonical pathway analysis by Ingenuity software showed the pathways that are affected by 
these differentially expressed genes. The analysis showed that several pro-oncogenic signaling 
pathways were upregulated (HGF, IGF-1 and NGF and ERK-5). Oxidative phosphorylation is a 
process that is downregulated in cancers since cancer cells are in a state of hypoxia and unable 
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to perform oxidative phosphorylation. Instead, they use glycolysis as their preferred source of 
energy. eIF2 is a signaling pathway that is required for successful translation of proteins. 
Approximately 50 percent of the genes involved in both of these pathways were found to be 
downregulated in TAF2high group. The possible upstream regulators of these differentially 
regulated genes were determined. Some of the notable activators of these genes include 
molecules involved in oncogenic pathways like CD24, MAP4K4, HGF, CCND1 and 
VEGF. Inhibition of the tumor suppressor gene RB1 and several miRNAs were identified 
to cluster with TAF2high group. 
 
TAF2 is a protein that is involved in transcription of genes by RNA polymerase II. It is a 
factor that is dispensable for basal transcription but, required for activated transcription. 
The overexpression of TAF2 in HCC patients was confirmed in silico, in vitro (in cell lines) 
and in vivo (in liver sections). Stable cell lines with knockdown of TAF2 were created to 
check for the effect of the knockdown on various cancer hallmarks like proliferation, 
migration and invasion. Two different assays (MTT and colony formation assays) were 
performed to compare the proliferation capacity of TAF2 knockdown cell lines and control 
cell lines. TAF2 knockdown cell lines did not show a decrease in cellular proliferation. On 
performing a wound healing assay to compare the migration capacity of TAF2 knockdown 
and control cell lines, the knockdowns showed a delay in wound healing. A Matrigel 
invasion assay was then performed to compare the invasion capacity of TAF2 knockdown 
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and control cells. TAF2 knockdown cells showed a decreased ability to invade through 
the Matrigel. Thus, knockdown of TAF2 did not affect proliferation but, inhibited migration 
and invasion. 
 
An earlier study found TAF2 to be involved in regulating cyclin levels (cyclin A and B1) 
and hence cell cycle progression. It was shown that transient knockout of TAF2 in HeLa 
cells resulted in a decrease in cyclin A and B1 levels and cell cycle arrest in G2/M phases.  
Also, cyclin D1 was one of the possible downstream targets of TAF2 identified through 
canonical pathway analysis that was performed as a part of this study. Given the above, 
it was contradicting that a decrease in cellular proliferation was not seen in the 
knockdowns. To explain this, lysates from the knockdowns were probed for cyclins A and 
B1. A decrease was not observed in cyclin A or cyclin B1 levels in the knockdowns. This 
gives a possible explanation for not seeing a decrease in cellular proliferation in the 
knockdowns. But, the reason for not seeing a decrease in cyclin levels in the knockdowns 
is yet to be determined. A possible explanation for this is that the stable cell lines used in 
this study are TAF2 knockdown cell lines and not TAF2 knockout cells lines. These cells 
have 40 to 60 percent TAF2 in them. This remaining TAF2 could be sufficient to keep 
cyclin levels normal and help cell cycle progress without any hindrance.  
 
Epithelial Mesenchymal Transition (EMT) plays a key role in a tumor cell obtaining the 
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ability to migrate and invade the basement membrane. Inhibition of migration and invasion 
was observed in the knockdowns. To determine if there is a reversal of EMT transition 
occurring in the knockdowns, the cell lysates were probed for EMT markers E-Cadherin 
and N-Cadherin. An increase in E-Cadherin was observed. Unlike typical cadherin 
switching, this was not accompanied by a decrease in N-Cadherin. To find the molecule 
causing an increase in E-Cadherin levels, the lysates were probed for known regulators 
of E-cadherin. Snail, which is a known negative regulator of E-Cadherin was found to 
decrease in the knockdowns. Based on our observations, we can conclude that 
knockdown of TAF2 decreases Snail levels which causes increase in E-Cadherin thus 
making the cells more epithelial and hence unable to migrate and invade.  
 
The phenotypic difference observed in the knockdowns is due to a decrease in Snail 
protein level. But, it is yet to be understood how TAF2 causes this decrease in Snail 
protein. The knockdowns need to be probed for known regulators of Snail like smad 
proteins. Since no decrease in the mesenchymal marker N-Cadherin is seen, it will be 
worthwhile probing for other known mesenchymal markers (Vimentin, Fibronectin, Type I 
collagen, Laminin 5 and certain integrins). There are other known EMT regulators (Slug, 
Snail, Twist, Zeb1 and Zeb2) that can be probed too. This will help reach a conclusion 
about the pathway that TAF2 is involved in to promote EMT. Given that we have obtained 
a difference in migration and invasion capacity of the cells, staining these cells will 
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determine if there is a difference in actin organization.  
 
Also, bioinformatic data obtained from canonical pathway analysis performed during the 
beginning of this study helps explain this difference in migration and invasion. mTOR 
signaling, which is involved in tumor cell motility, invasion and metastasis121, was found 
to be deregulated in TAF2high group. Also, some of the possible downstream regulators 
of TAF2 included Rictor which is a component of the mTORC2 signaling complex and 
regulates cell migration122, CD24 which is a cell adhesion molecule, MAP4K4 which 
controls cell motility123 HGF or scatter factor which is a cell motility inducer124 and VEGF 
which is a cell migration inducer125. It is necessary to study if the observed decrease in 
invasion and migration is due to any of these factors. 
 
With evidence from previous studies for involvement of TAF2 in cell cycle regulation and 
maintaining cyclin levels, it is important to determine if we did not see a difference in 
cellular proliferation due to the remaining TAF2 in the cells or because TAF2 does not 
regulate cyclins. It is therefore necessary to create a stable clone with complete knock 
out of TAF2 and study if a change in cell proliferation, migration and invasion is obtained. 
Another future direction of this project would be to create stable clones that over express 
TAF2 and study its effect on cellular proliferation, migration and invasion. Performing a 
Differential Expression (DE) analysis using RNA-seq to determine the difference in gene 
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expression between the knockout and overexpression cell lines will be help gain an 
insight into the genes that are affected by TAF2. 
In summary, we have shown that TAF2 is important for tumor migration and invasion. It 
is a potential oncogene that needs to be further studied to establish its role in 
tumorigenesis.  
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